CO2020013468A2 - Agentes de unión a c3 y métodos para su uso - Google Patents
Agentes de unión a c3 y métodos para su usoInfo
- Publication number
- CO2020013468A2 CO2020013468A2 CONC2020/0013468A CO2020013468A CO2020013468A2 CO 2020013468 A2 CO2020013468 A2 CO 2020013468A2 CO 2020013468 A CO2020013468 A CO 2020013468A CO 2020013468 A2 CO2020013468 A2 CO 2020013468A2
- Authority
- CO
- Colombia
- Prior art keywords
- binding agents
- methods
- encode
- antibodies
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862652253P | 2018-04-03 | 2018-04-03 | |
| PCT/US2019/025123 WO2019195136A1 (en) | 2018-04-03 | 2019-04-01 | C3-binding agents and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2020013468A2 true CO2020013468A2 (es) | 2020-11-10 |
Family
ID=66630340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2020/0013468A CO2020013468A2 (es) | 2018-04-03 | 2020-10-26 | Agentes de unión a c3 y métodos para su uso |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11136381B2 (https=) |
| EP (1) | EP3790897A1 (https=) |
| JP (2) | JP7477457B2 (https=) |
| KR (1) | KR20200138290A (https=) |
| CN (1) | CN112105638A (https=) |
| AR (1) | AR117565A1 (https=) |
| AU (1) | AU2019248557A1 (https=) |
| BR (1) | BR112020019907A2 (https=) |
| CA (1) | CA3093356A1 (https=) |
| CL (2) | CL2020002522A1 (https=) |
| CO (1) | CO2020013468A2 (https=) |
| IL (1) | IL277404A (https=) |
| MX (1) | MX2020010323A (https=) |
| PE (1) | PE20212132A1 (https=) |
| PH (1) | PH12020500664A1 (https=) |
| SG (1) | SG11202008897SA (https=) |
| TW (1) | TWI833742B (https=) |
| WO (1) | WO2019195136A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019195136A1 (en) | 2018-04-03 | 2019-10-10 | Ngm Biopharmaceuticals, Inc. | C3-binding agents and methods of use thereof |
| WO2021226442A2 (en) * | 2020-05-08 | 2021-11-11 | Ngm Biopharmaceuticals, Inc. | Therapeutic uses of c3-binding agents |
| US20230381269A1 (en) * | 2020-09-21 | 2023-11-30 | Apellis Pharmaceuticals, Inc. | Methods of treating eye disorders |
| CN116848136A (zh) * | 2021-02-12 | 2023-10-03 | 勃林格殷格翰国际有限公司 | 补体c3抗原结合蛋白 |
| IL313655A (en) | 2021-12-22 | 2024-08-01 | Boehringer Ingelheim Int | Anti-C3 antibodies and their antigen-binding fragments and their uses for the treatment of eyes or eye diseases |
| WO2024086555A1 (en) | 2022-10-17 | 2024-04-25 | Ngm Biopharmaceuticals, Inc. | Uses of anti-c3 antibodies |
| CN117447601B (zh) * | 2023-12-22 | 2024-03-08 | 北京索莱宝科技有限公司 | 猪IgM的抗体、抗体组合物及其应用 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA01002580A (es) * | 1998-09-10 | 2002-04-08 | Univ Virginia | Anticuerpos para c3b(1) para el suministro de agentes de diagnostico y terapeuticos para celulas cancerosas. |
| WO2004031240A1 (en) * | 2002-10-04 | 2004-04-15 | Stichting Sanquin Bloedvoorziening | Monoclonal antibody anti-c3-2 directed against the third component of complement (c3) and its use in methods to inhibit complement activation |
| US7816497B2 (en) | 2002-10-30 | 2010-10-19 | University Of Kentucky | Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration |
| WO2004041867A2 (en) * | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders |
| US20090004183A1 (en) | 2004-07-23 | 2009-01-01 | Taylor Ronald P | Compositions and Methods for Regulating the Alternative Pathway of Complement |
| WO2006083533A2 (en) | 2005-01-14 | 2006-08-10 | The Regents Of The University Of California | Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders |
| US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| EP3299027A1 (en) | 2005-11-04 | 2018-03-28 | Genentech, Inc. | Use of complement pathway inhibitors to treat ocular diseases |
| PL2148691T3 (pl) | 2007-02-05 | 2015-12-31 | Apellis Pharmaceuticals Inc | Analogi kompstatyny do stosowania w leczeniu stanów zapalnych układu oddechowego |
| US9745367B2 (en) | 2007-03-23 | 2017-08-29 | Novelmed Theraputics, Inc. | Alternative pathway specific antibodies for treating arthritis |
| US8192742B2 (en) | 2007-03-23 | 2012-06-05 | NovelMed Therapeutics | Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof |
| BRPI0812767A2 (pt) | 2007-06-07 | 2014-12-02 | Genentech Inc | Anticorpos para c3b e métodos para prevenção e tratamento de distúrbios associados ao complemento |
| US20100291106A1 (en) * | 2009-05-06 | 2010-11-18 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c3b |
| RU2548807C2 (ru) | 2009-05-20 | 2015-04-20 | Торэй Индастриз, Инк. | Пептиды, проникающие в клетку |
| US9291622B2 (en) | 2009-05-21 | 2016-03-22 | Apellis Pharmaceuticals, Inc. | Complement assays and uses thereof |
| US20130177567A1 (en) | 2010-05-18 | 2013-07-11 | Sydansk Universitet | Novel c3c epitope, antibodies binding thereto, and use thereof |
| US9815890B2 (en) | 2010-06-22 | 2017-11-14 | The Regents Of The University Of Colorado, A Body Corporate | Antibodies to the C3d fragment of complement component 3 |
| US9243060B2 (en) | 2012-04-03 | 2016-01-26 | Novelmed Therapeutics, Inc. | Humanized anti-factor C3b antibodies and uses thereof |
| WO2015099838A2 (en) | 2013-12-24 | 2015-07-02 | Novelmed Therapeutics, Inc. | Compositions and methods of treating ocular diseases |
| SG10202003996YA (en) | 2014-05-05 | 2020-06-29 | Regeneron Pharma | Humanized c5 and c3 animals |
| US10815276B2 (en) | 2014-05-21 | 2020-10-27 | Entrada Therapeutics, Inc. | Cell penetrating peptides and methods of making and using thereof |
| AU2015360502A1 (en) * | 2014-12-10 | 2017-06-29 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
| US20180346531A1 (en) | 2015-09-15 | 2018-12-06 | Regents Of The University Of California | Compositions and methods for delivering biotherapeutics |
| EP3359555B1 (en) | 2015-10-07 | 2023-12-20 | Apellis Pharmaceuticals, Inc. | Dosing regimens |
| RU2630647C1 (ru) * | 2016-05-27 | 2017-09-11 | Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства | ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К КОНФОРМАЦИОННОМУ ЭПИТОПУ С3 КОМПОНЕНТА КОМПЛЕМЕНТА ЧЕЛОВЕКА, ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), И ШТАММ КЛЕТОК ЯИЧНИКОВ КИТАЙСКОГО ХОМЯЧКА CHO-humC34-ПРОДУЦЕНТ ДАННОГО ГУМАНИЗИРОВАННОГО АНТИТЕЛА |
| EP3654941A1 (en) | 2017-07-17 | 2020-05-27 | Keith Roizman | Topical delivery of therapeutic agents comprising cell-penetrating peptides for use for the treatment of age-related macular degeneration and other eye diseases |
| WO2019195136A1 (en) | 2018-04-03 | 2019-10-10 | Ngm Biopharmaceuticals, Inc. | C3-binding agents and methods of use thereof |
-
2019
- 2019-04-01 WO PCT/US2019/025123 patent/WO2019195136A1/en not_active Ceased
- 2019-04-01 CN CN201980027315.6A patent/CN112105638A/zh active Pending
- 2019-04-01 SG SG11202008897SA patent/SG11202008897SA/en unknown
- 2019-04-01 PE PE2020001505A patent/PE20212132A1/es unknown
- 2019-04-01 EP EP19725880.9A patent/EP3790897A1/en not_active Withdrawn
- 2019-04-01 CA CA3093356A patent/CA3093356A1/en active Pending
- 2019-04-01 TW TW108111549A patent/TWI833742B/zh active
- 2019-04-01 KR KR1020207030405A patent/KR20200138290A/ko active Pending
- 2019-04-01 US US16/371,684 patent/US11136381B2/en active Active
- 2019-04-01 AR ARP190100853A patent/AR117565A1/es unknown
- 2019-04-01 BR BR112020019907-9A patent/BR112020019907A2/pt unknown
- 2019-04-01 AU AU2019248557A patent/AU2019248557A1/en not_active Abandoned
- 2019-04-01 MX MX2020010323A patent/MX2020010323A/es unknown
- 2019-04-01 JP JP2020554097A patent/JP7477457B2/ja active Active
-
2020
- 2020-09-16 IL IL277404A patent/IL277404A/en unknown
- 2020-09-29 CL CL2020002522A patent/CL2020002522A1/es unknown
- 2020-10-01 PH PH12020500664A patent/PH12020500664A1/en unknown
- 2020-10-26 CO CONC2020/0013468A patent/CO2020013468A2/es unknown
-
2021
- 2021-08-02 CL CL2021002039A patent/CL2021002039A1/es unknown
- 2021-08-19 US US17/406,991 patent/US11767359B2/en active Active
-
2023
- 2023-08-10 US US18/447,741 patent/US20230382985A1/en not_active Abandoned
-
2024
- 2024-02-13 JP JP2024019502A patent/JP2024056851A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7477457B2 (ja) | 2024-05-01 |
| EP3790897A1 (en) | 2021-03-17 |
| CN112105638A (zh) | 2020-12-18 |
| TW202003559A (zh) | 2020-01-16 |
| RU2020135712A (ru) | 2022-05-04 |
| JP2024056851A (ja) | 2024-04-23 |
| US20230382985A1 (en) | 2023-11-30 |
| JP2021520195A (ja) | 2021-08-19 |
| US20190322730A1 (en) | 2019-10-24 |
| KR20200138290A (ko) | 2020-12-09 |
| SG11202008897SA (en) | 2020-10-29 |
| WO2019195136A1 (en) | 2019-10-10 |
| US20220119508A1 (en) | 2022-04-21 |
| CL2020002522A1 (es) | 2021-02-26 |
| MX2020010323A (es) | 2021-01-08 |
| PE20212132A1 (es) | 2021-11-05 |
| CA3093356A1 (en) | 2019-10-10 |
| AR117565A1 (es) | 2021-08-18 |
| US11136381B2 (en) | 2021-10-05 |
| BR112020019907A2 (pt) | 2021-01-05 |
| TWI833742B (zh) | 2024-03-01 |
| IL277404A (en) | 2020-11-30 |
| AU2019248557A1 (en) | 2020-09-24 |
| CL2021002039A1 (es) | 2022-04-01 |
| US11767359B2 (en) | 2023-09-26 |
| PH12020500664A1 (en) | 2021-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020013468A2 (es) | Agentes de unión a c3 y métodos para su uso | |
| CO2020016619A2 (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso | |
| CL2020003031A1 (es) | Agentes aglutinantes del psma y usos de estos. | |
| DOP2021000049A (es) | Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y métodos de uso de anticuerpos anti-hla-g | |
| CO2022008272A2 (es) | Agentes de unión a ilt3 y métodos de uso de los mismos | |
| CO2021016907A2 (es) | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3 | |
| CL2024003895A1 (es) | Proteínas que se unen a nkg2d, flt3 y cd16; composición farmacéutica; y su uso. | |
| CL2022003004A1 (es) | Agentes de unión a ilt y métodos para su uso | |
| MX2019009468A (es) | Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer. | |
| CO2018009995A2 (es) | Proteínas de unión y métodos de uso de las mismas | |
| MX2017014955A (es) | Agentes de union a inmunorreceptor de celulas t con dominios ig y motivo de inhibicion basado en tirosina de inmunorreceptor (tigit) y usos de los mismos. | |
| CO2018000992A2 (es) | Anticuerpos anti-pd-1 novedosos | |
| MX2022015258A (es) | Anticuerpos anti-cxcr5 y composiciones y usos de los mismos. | |
| MX2020004561A (es) | Anticuerpos biespecificos que se unen a alk-1 y bmpr-2. | |
| CL2021000316A1 (es) | Proteínas de unión multiespecíficas que se unen a bcma, nkg2d y cd16 y métodos de uso | |
| CL2016003056A1 (es) | Dinucleótidos ciclicos moduladores de sting; composición y combinación farmacéutica que los comprende y uso de los mismos para el tratamiento de enfermedades tales como inflamación, enfermedades alérgicas y autoinmunes, enfermedades infecciosas y cancer. | |
| MX2018004515A (es) | Agentes de anticuerpo especificos para cd19 humano y usos de los mismos. | |
| MX2017006626A (es) | Cadenas ligeras comunes y metodos de uso. | |
| CL2022003684A1 (es) | Agentes de unión a lair-1 y métodos para su uso | |
| CL2020001629A1 (es) | Anticuerpos de unión a hla-a2/wt1. | |
| MX2023010076A (es) | Moleculas de union al transcrito 7 similar a inmunoglobulina (ilt7) y metodos de uso de las mismas. | |
| CL2020003447A1 (es) | Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas | |
| PE20220297A1 (es) | Neutralizacion del virus chikungunya mediada por anticuerpos | |
| AR093620A1 (es) | Anticuerpos bmp-6 | |
| AR101486A1 (es) | Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso |